The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian-danish 5-year study

In this study, we investigated the effects of selegiline on levodopa treatment and parkinsonian disability over several years of treatment in patients with early Parkinson's disease (PD). The 163 patients were randomized to receive either selegiline or placebo in addition to levodopa in a double‐blind, parallel‐group study design, and the patients were to be followed up until a defined termination point or for 5 years. All patients had previously either never (two thirds) or for